Connect Biopharma Holdings Limited
NASDAQ:CNTB · NASDAQ Global Market
+$0.02 today
Vol 0.26M · Avg 0.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-132.2%
avg 66.6%
ROIC
-135.7%
avg -85.6%
ROA
-98.9%
avg -135.8%
Analysis
ROA is currently the strongest return metric at -98.9% versus its period average of -135.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Barry D. Quart | Chief Executive Officer & Director | $980,224.00 | — | 69 | $128,887.00 | 0.20% |
David L. Szekeres | President | $734,970.00 | — | 52 | $215,739.00 | 0.34% |
Lisa Peraza | Senior Vice President of Finance | $571,126.00 | — | 49 | $45,189.00 | 0.07% |
Lei Sun | Vice President of Biologics & Head of CMC | — | — | 62 | — | — |
Srikanth Pendyala | Senior Vice President of Clinical Development(Consultant) | — | — | — | — | — |
Jeff Cohn | General Counsel & Corporate Secretary | — | — | 44 | — | — |
Sean T. Ristine | Vice President of Human Resources | — | — | 56 | — | — |
Kimberly J. Manhard | Executive Vice President & Chief Development Officer | — | — | 66 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$4.37M
Sells
0
$0.00
Net Sentiment
+$4.37M
Net buying
Most Active
Huang James
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 29, 2026 | Huang James Indirect | Buy | 150.0K | $2.48 | $371,610.00 | |
| Mar 31, 2026 | Huang James Indirect | Buy | 1.16M | $3.45 | $4,002,000.00 |
Analysis
Insiders reported 2 buys worth $4.37M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $4.37M. Huang James was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Metagenomi, Inc. Common Stock
MGX
$45.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages CNTB?
Connect Biopharma Holdings Limited (CNTB) lists 8 active executives. The top listed executive is Barry D. Quart, Chief Executive Officer & Director.
Are CNTB insiders buying or selling?
Recent insider activity shows net buying of $4.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.